Introduction

Epidermal Growth Factor Receptor (EGFR), is a tyrosine kinase receptor and is considered as an oncogene. EGFR is involved in regulation of cellular proliferation, differentiation and survival. Mutations in EGFR exons 18, 19, 20 and 21 are associated with the development of different human cancers specially None Small Cell Lung Carcinoma (NSCLC), and galioblastoma. Since, the choice of anti-EGFR therapies are highly dependent on the EGFR mutations, it is essential that patients are tested for these mutations.

This kit provides ready to use reagents for detection of 34 mutations. Detected mutations include three point mutations in exon 18 (G719A, G719S and G719C without differentiating them), 24 deletions in exon 19 (without differentiation between them), three insertion (without differentiation between them) and two point mutation in exon 20 (S768I and T790M) and two point mutations in exon 21 (L858R, L861Q). For more information see table1.